Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.64% | 6.48% | 59.59% | 30.46% | 3.59% |
| Total Depreciation and Amortization | 28.15% | 9.28% | 15.50% | 15.02% | 1.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | 23.81% | -- |
| Total Other Non-Cash Items | 234.81% | -30.44% | -75.53% | 7.39% | -139.67% |
| Change in Net Operating Assets | -193.92% | 13.14% | 191.14% | -69.19% | -5.02% |
| Cash from Operations | -48.20% | 4.87% | 74.39% | -14.81% | -9.37% |
| Capital Expenditure | 4.42% | 22.99% | -227.76% | -61.34% | -50.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20,229.61% | 119.60% | -1,876.82% | 80.98% | 94.58% |
| Cash from Investing | -5,114.19% | 90.55% | -674.01% | 64.95% | 66.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -7.69% | -- |
| Issuance of Common Stock | 189.87% | -2.85% | 61.68% | 57.43% | -5.95% |
| Repurchase of Common Stock | 82.27% | -19.14% | 18.83% | 69.21% | -196.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5,500.00% | 0.00% | 20.00% | 22.22% | -133.33% |
| Cash from Financing | 472.19% | -22.19% | 20.81% | 80.27% | -197.94% |
| Foreign Exchange rate Adjustments | -19.51% | -106.47% | -232.13% | 115.43% | -117.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,307.89% | 118.88% | 268.46% | 120.71% | -105.20% |